MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31

MANNKIND CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$3.09+0.05 (+1.64%)

Close on Oct 19, 2026

Market cap: $955.40M
P/E (TTM): –
Dividend yield: –

MANNKIND CORP income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	349	286	199	100	75	65	63	28	12	175	0	0	0	0.04	0.05	0.09	–	–	–	–
Cost of Revenue	27	17	21	16	17	15	20	19	17	17	65	–	–	–	–	–	–	–	–	–
Gross Profit	322	268	178	84	59	50	43	8.47	-5.48	158	-65	–	–	–	–	–	–	–	–	–
Research & Development	66	46	31	20	12	6.25	6.90	8.74	14	15	30	100	110	102	100	112	156	–	–	–
Selling, General & Admin	144	94	94	91	77	59	75	80	75	47	41	79	–	–	–	–	–	–	–	–
Selling & Marketing	–	–	–	–	–	–	–	–	–	20	1.59	3.56	–	–	–	–	–	–	–	–
General & Administrative	–	–	43	38	32	25	–	–	–	27	39	76	60	45	41	40	53	–	–	–
Operating Expenses	88	77	63	57	39	25	–	–	–	–	345	180	169	147	141	153	210	–	–	–
Total Costs & Expenses	310	213	190	164	122	113	108	104	120	107	345	180	–	–	–	–	–	–	–	–
Operating Income	39	73	8.68	-64	-47	-48	-45	-77	-108	67	-345	-180	-169	-147	-141	-152	-210	–	–	–
Interest Expense	14	12	15	15	15	9.47	6.30	5.12	9.49	16	21	18	22	22	22	17	4.77	–	–	–
Interest & Investment Income	8.05	13	6.15	2.51	0.11	0.17	1.00	0.50	0.29	0.09	0.02	0.01	0.01	0.01	0.02	0.04	0.07	–	–	–
Other Non-Operating Income	-37	-42	-19	-23	-34	-9.55	-7.31	-10	-9.09	58	-24	-19	-0.64	-1.19	1.54	-0.73	0.05	–	–	–
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	2.04	6.04	1.90	0.40	–	–	–	–	–	–	–
Asset Impairment Charges	0	0	–	0	0.11	1.89	–	–	0.20	1.30	141	0	0	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	-0.57	–	–	–	–	–	0.11	-0.20	-1.26	-141	-0.10	–	–	–	–	–	–	–	–
Legal Settlements	–	–	-0.20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	1.41	31	-10	-87	-81	-57	-52	-87	-117	126	-368	-198	-191	-170	-161	-171	-220	–	–	–
Income Tax Expense	-4.46	2.93	1.56	0	0	-0.22	0	0.24	0.05	0	0	0	0	-0.41	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	5.86	28	-12	-87	-81	-57	-52	-87	-117	126	–	–	–	–	–	–	–	–	–	–
Net Income	5.86	28	-12	-87	-81	-57	-52	-87	-117	126	-368	-198	-191	-169	-161	-171	-220	-303	-293	-231
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	-191	-169	-161	-171	-220	–	–	–
EPS (Basic)(per share)	0.02	0.10	-0.04	-0.34	-0.32	-0.26	-0.27	-0.60	-1.13	1.37	-4.54	-2.57	-3.20	-4.70	-6.60	-7.50	-10.35	–	–	–
EPS (Diluted)(per share)	0.02	0.10	-0.04	-0.34	-0.32	-0.26	-0.27	-0.60	-1.13	1.36	-4.54	-2.57	-3.20	-4.70	-6.60	-7.50	-10.35	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	306	274	267	257	249	223	196	144	104	92	81	77	60	36	–	–	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	314	284	267	257	249	223	196	144	104	92	81	77	60	36	–	–	–	–	–	–
EBITDA	51	80	13	-61	-45	-46	-44	-74	-105	71	-334	-170	-158	-134	-126	-136	-191	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 89.8%
Operating margin: 2.3%
Net margin: -11.1%
Return on equity, FY2025: -9.0%

Financial strength

Current ratio: 1.72
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 37.0%

Valuation

P/E ratio: –
Price to sales: 2.43
Price to book: –
Dividend yield: –